リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Early P2Y 12 Inhibitor Single Antiplatelet Therapy for High-Bleeding Risk Patients After Stenting - PENDULUM Mono 24-Month Analysis」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Early P2Y 12 Inhibitor Single Antiplatelet Therapy for High-Bleeding Risk Patients After Stenting - PENDULUM Mono 24-Month Analysis

NAKAGAWA Yoshihisa 00378613 KADOTA Kazushige NAKAO Koichi SHITE Junya YOKOI Hiroyoshi KOZUMA Ken TANABE Kengo AKASAKA Takashi SHINKE Toshiro UENO Takafumi HIRAYAMA Atsushi UEMURA Shiro IIJIMA Raisuke HARADA Atsushi KURODA Takeshi TAKITA Atsushi MURAKAMI Yoshitaka 90305855 0000-0002-8134-0327 SAITO Shigeru NAKAMURA Masato 滋賀医科大学

2022

概要

Background:
In PENDULUM mono, Japanese patients with high bleeding risk (HBR) received short-term dual antiplatelet therapy (DAPT) followed by single antiplatelet therapy (SAPT) with prasugrel after percutaneous coronary intervention (PCI). One-year data from PENDULUM mono showed better outcomes with prasugrel monotherapy after short-term DAPT compared with matched patients in the PENDULUM registry with longer DAPT durations according to guidelines at that time. This study presents 2-year results.Methods and Results: We compared 24-month data from PENDULUM mono (n=1,107; de-escalation strategy group) and the PENDULUM registry (n=2,273; conventional strategy group); both were multicenter, non-interventional, prospective registry studies, using the inverse probability of treatment weighting (IPTW) method. In the PENDULUM mono group, the cumulative incidence of clinically relevant bleeding (CRB) at 24 months post-PCI (primary endpoint) was 6.8%, and that of major adverse cardiac and cerebrovascular events (MACCE) was 8.9%. After IPTW adjustment, the cumulative incidence of CRB was 5.8% and 7.2% in PENDULUM mono and the PENDULUM registry, respectively (hazard ratio [HR] 0.77; 95% confidence interval [CI] 0.57-1.04; P=0.086), and that of MACCE was 8.0% and 9.5%, respectively (HR 0.77; 95% CI 0.59-1.01; P=0.061).
Conclusions:
Japanese PCI patients with HBR prescribed prasugrel SAPT after short-term DAPT had a lower ischemic event risk than those prescribed long-term DAPT, and this was particularly relevant for ischemic events after 1 year.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting: Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339: 1665 – 1671.

2. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155 – 2166.

3. Palmerini T, Benedetto U, Bacchi-Reggiani L, Della Riva D, Biondi-Zoccai G, Feres F, et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: A pairwise and Bayesian network meta-anal- ysis of randomized trials. Lancet 2015; 385: 2371 – 2382.

4. Toyota T, Shiomi H, Morimoto T, Natsuaki M, Kimura T. Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: A comparison between the DAPT study and 9 other trials evaluating DAPT duration. PLoS One 2017; 12: e0174502.

5. Nakamura M, Kimura K, Kimura T, Ishihara M, Otsuka F, Kozuma K, et al. JCS 2020 guideline focused update on antithrom- botic therapy in patients with coronary artery disease. Circ J 2020; 84: 831 – 865.

6. Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, et al. Effect of 1-month dual antiplatelet therapy fol- lowed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial. JAMA 2019; 321: 2414 – 2427.

7. Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med 2019; 381: 2032 – 2042.

8. Kang J, Park KW, Palmerini T, Stone GW, Lee MS, Colombo A, et al. Racial differences in ischaemia/bleeding risk trade-off during anti-platelet therapy: Individual patient level landmark meta-analysis from seven RCTs. Thromb Haemost 2019; 119: 149 – 162.

9. Kohsaka S, Miyata H, Ueda I, Masoudi FA, Peterson ED, Maekawa Y, et al. An international comparison of patients undergoing percutaneous coronary intervention: A collaborative study of the National Cardiovascular Data Registry (NCDR) and Japan Cardiovascular Database-Keio interhospital Cardio- vascular Studies (JCD-KiCS). Am Heart J 2015; 170: 1077 – 1085.

10. Mak KH, Bhatt DL, Shao M, Hankey GJ, Easton JD, Fox KAA, et al. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Athero- thrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. Am Heart J 2009; 157: 658 – 665.

11. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: Col- laborative meta-analysis of individual participant data from ran- domized trials. Lancet 2009; 373: 1849 – 1860.

12. Nakamura M, Kadota K, Nakao K, Nakagawa Y, Shite J, Yokoi H, et al. Single antiplatelet therapy with prasugrel vs. dual antiplatelet therapy in Japanese percutaneous coronary interven- tion patients with high bleeding risk. Circ J 2021; 85: 785 – 793.

13. Nakamura M, Morino Y, Kakuta T, Hata Y, Takamisawa I, Tanabe K, et al. Monotherapy with prasugrel after dual-anti- platelet therapy for Japanese percutaneous coronary intervention patients with high bleeding risk: A prospective cohort study (PENDULUM mono study). Circ J 2021; 85: 27 – 36.

14. Nakamura M, Kadota K, Takahashi A, Nakamura M, Kadota K, Takahashi A, et al. Relationship between platelet reactivity and ischemic and bleeding events after percutaneous coronary interven- tion in East Asian patients: 1-year results of the PENDULUM registry. J Am Heart Assoc 2020; 9: e015439.

15. ICH Expert Working Group. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6(R1). https:// www.pmda.go.jp/files/000156725.pdf (accessed April 11, 2022).

16. Nakamura M, Kadota K, Nakao K, Nakagawa Y, Shite J, Yokoi H, et al. High bleeding risk and clinical outcomes in East Asian patients undergoing percutaneous coronary intervention: The PENDULUM registry. EuroIntervention 2021; 16: 1154 – 1162.

17. Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013; 382: 1714 – 1722.

18. Kaikita K, Yasuda S, Akao M, Ako J, Matoba T, Nakamura M, et al. Bleeding and subsequent cardiovascular events and death in atrial fibrillation with stable coronary artery disease: Insights from the AFIRE trial. Circ Cardiovasc Interv 2021; 14: e010476.

19. Koo BK, Kang J, Park KW, Rhee TM, Yang HM, Won KB et al. Aspirin versus clopidogrel for chronic maintenance monother- apy after percutaneous coronary intervention (HOST-EXAM): An investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet 2021; 397: 2487 – 2496.

20. Tomaniak M, Chichareon P, Onuma Y, Deliargyris EN, Takahashi K, Kogame N, et al. Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes: A post hoc analysis of the randomized GLOBAL LEADERS trial. JAMA Cardiol 2019; 4: 1092 – 1101.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る